Cite

HARVARD Citation

    Kondo, S. et al. (n.d.). 314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer. European journal of cancer. pp. S59-. [Online]. 
  
Back to record